{"id":50983,"date":"2025-12-16T22:20:16","date_gmt":"2025-12-16T14:20:16","guid":{"rendered":"https:\/\/flcube.com\/?p=50983"},"modified":"2025-12-16T22:20:17","modified_gmt":"2025-12-16T14:20:17","slug":"konruns-doses-first-patient-in-phase-2-esophageal-cancer-trial-for-kc1036","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50983","title":{"rendered":"Konruns Doses First Patient in Phase 2 Esophageal Cancer Trial for KC1036"},"content":{"rendered":"\n

Konruns Pharmaceutical Co., Ltd.<\/strong> (SHA: 603590<\/a>) announced first patient dosing in the Phase 2 KC1036\u2011COM\u201101 study<\/strong>, evaluating KC1036 tablets<\/strong> in combination with a PD\u20111 antibody and platinum\u2011based chemotherapy<\/strong> for first\u2011line treatment of advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC)<\/strong>. KC1036 is a Category\u202f1 innovative drug targeting VEGFR2 and AXL<\/strong>, with ongoing studies in digestive system tumors, thymic tumors, and pediatric Ewing\u2019s sarcoma.<\/p>\n\n\n\n

Clinical Trial Overview<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Study ID<\/strong><\/td>KC1036\u2011COM\u201101<\/td><\/tr>
Phase<\/strong><\/td>Phase\u202f2<\/td><\/tr>
Design<\/strong><\/td>Combination therapy: KC1036 + PD\u20111 antibody + platinum\u2011based chemotherapy<\/td><\/tr>
Population<\/strong><\/td>Advanced recurrent or metastatic esophageal squamous cell carcinoma (first\u2011line)<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Objective Response Rate (ORR) and progression\u2011free survival (PFS)<\/td><\/tr>
Drug Class<\/strong><\/td>Category\u202f1 innovative chemical drug (VEGFR2\/AXL inhibitor)<\/td><\/tr>
Additional Indications<\/strong><\/td>Digestive system tumors, thymic tumors, pediatric Ewing\u2019s sarcoma (all in clinical studies)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>KC1036<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Multi\u2011target inhibition (VEGFR2, AXL) with anti\u2011angiogenic and anti\u2011tumor activity<\/td><\/tr>
Innovation<\/strong><\/td>Category\u202f1 innovative drug independently developed by Konruns<\/td><\/tr>
Clinical Data<\/strong><\/td>Demonstrated outstanding anti\u2011tumor activity and favorable safety\/tolerability in existing studies<\/td><\/tr>
Route<\/strong><\/td>Oral tablets (patient\u2011convenient)<\/td><\/tr>
Market Position<\/strong><\/td>First VEGFR2\/AXL inhibitor in China entering Phase\u202f2 for ESCC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Implication<\/th><\/tr><\/thead>
China ESCC Incidence<\/strong><\/td>~300,000 new cases annually (2024)<\/td>90% are squamous cell subtype; high recurrence rate<\/td><\/tr>
Advanced ESCC Market<\/strong><\/td>\u00a512\u201115\u202fbillion (\u2248\u202fUS$1.7\u20112.1\u202fB)<\/td>Dominated by PD\u20111\/PD\u2011L1 inhibitors + chemotherapy<\/td><\/tr>
KC1036 Peak Sales<\/strong><\/td>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (\u2248\u202fUS$112\u2011170\u202fM)<\/td>10\u201115% share if approved in first\u2011line ESCC<\/td><\/tr>
Competitive Advantage<\/strong><\/td>VEGFR2\/AXL inhibition<\/strong> may overcome resistance to PD\u20111 monotherapy<\/td>Synergistic with immunotherapy backbone<\/td><\/tr>
Pipeline Expansion<\/strong><\/td>Thymic tumors and Ewing\u2019s sarcoma represent niche but high\u2011value<\/strong> indications<\/td>Additional revenue streams if approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n